ArticleFrontiers in oncology2025

Efficacy and safety of cadonilimab (PD-1/CTLA-4 bi-specific antibody) and adjuvant anti-angiogenesis therapy in treated, recurrent, or metastatic cervical cancer.

Fang Zhou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.